BACKGROUND:Irisin plays a crucial role in the physiological regulation of the body,advancing the browning process of white adipose tissue cells and exerting significant effects on the regulation of energy metabolism,thermogenesis,reduction of oxidative stress,and body mass loss.OBJECTIVE:To summarize the latest research progress in irisin and related diseases.METHODS:A computerized search of PubMed,MedReading,Web of Science,CNKI,WanFang,and VIP was performed to collect studies on the effect of irisin on relevant diseases.The search time was from January 1,2011 to April 13,2024.The search terms were"irisin,physical exercise,FNDC5,disease"in Chinese and English.According to the inclusion and exclusion criteria,71 papers were finally included for review.RESULTS AND CONCLUSION:Irisin has important roles in anti-inflammation,fat metabolism,bone metabolism,brain health,cancer,diabetes,cardiovascular disease and kidney disease.Moreover,exercise can promote the expression of irisin,and different forms of exercises have different effects on irisin levels.Acute exercise,long-term exercise,resistance exercise and high-intensity exercise can all enhance irisin levels.The discovery of irisin provides a new potential basis for exercise therapy,which is a promising therapeutic target due to the multiple biological functions of irisin,and shows potential therapeutic value in the treatment of human metabolic diseases and their complications,obesity,and cancer.Irisin has a promising application as a potential target for the treatment of obesity,cognitive function,cardiovascular,cancer and other diseases in clinical practice.However,its specific mechanism of action still needs to be studied in depth,and there may be side effects.In the future,an in-depth understanding of the mechanism of irisin is needed to provide a more adequate basis for the treatment of obesity,cognitive dysfunction,cardiovascular disease,and cancer.

BACKGROUND:Irisin plays a crucial role in the physiological regulation of the body,advancing the browning process of white adipose tissue cells and exerting significant effects on the regulation of energy metabolism,thermogenesis,reduction of oxidative stress,and body mass loss.OBJECTIVE:To summarize the latest research progress in irisin and related diseases.METHODS:A computerized search of PubMed,MedReading,Web of Science,CNKI,WanFang,and VIP was performed to collect studies on the effect of irisin on relevant diseases.The search time was from January 1,2011 to April 13,2024.The search terms were"irisin,physical exercise,FNDC5,disease"in Chinese and English.According to the inclusion and exclusion criteria,71 papers were finally included for review.RESULTS AND CONCLUSION:Irisin has important roles in anti-inflammation,fat metabolism,bone metabolism,brain health,cancer,diabetes,cardiovascular disease and kidney disease.Moreover,exercise can promote the expression of irisin,and different forms of exercises have different effects on irisin levels.Acute exercise,long-term exercise,resistance exercise and high-intensity exercise can all enhance irisin levels.The discovery of irisin provides a new potential basis for exercise therapy,which is a promising therapeutic target due to the multiple biological functions of irisin,and shows potential therapeutic value in the treatment of human metabolic diseases and their complications,obesity,and cancer.Irisin has a promising application as a potential target for the treatment of obesity,cognitive function,cardiovascular,cancer and other diseases in clinical practice.However,its specific mechanism of action still needs to be studied in depth,and there may be side effects.In the future,an in-depth understanding of the mechanism of irisin is needed to provide a more adequate basis for the treatment of obesity,cognitive dysfunction,cardiovascular disease,and cancer.

BACKGROUNDLowering intraocular pressure (IOP) is currently the only therapeutic approach in primary open-angle glaucoma. and the fixed-combination medications are needed to achieve sufficiently low target IOP. A multicenter prospective study in the Chinese population was needed to confirm the safety and efficacy of Bimatoprost/Timolol Fixed Combination Eye Drop in China. In this study, we evaluated the safety and efficacy of Bimatoprost/Timolol Fixed Combination with concurrent administration of its components in Chinese patients with open-angle glaucoma or ocular hypertension.

METHODSIn this multicenter, randomized, double-masked, parallel controlled study, patients with open-angle glaucoma or ocular hypertension who were insufficiently responsive to monotherapy with either topical β-blockers or prostaglandin analogues were randomized to one of two active treatment groups in a 1:1 ratio at 11 Chinese ophthalmic departments. Bimatoprost/timolol fixed combination treatment was a fixed combination of 0.03% bimatoprost and 0.5% timolol (followed by vehicle for masking) once daily at 19:00 P.M. and concurrent treatment was 0.03% bimatoprost followed by 0.5% timolol once daily at 19:00 P.M. The primary efficacy variable was change from baseline in mean diurnal intraocular pressure (IOP) at week 4 visit in the intent-to-treat (ITT) population. Primary analysis evaluated the non-inferiority of bimatoprost/ timolol fixed combination to concurrent with respect to the primary variable using a confidence interval (CI) approach. Bimatoprost/timolol fixed combination was to be considered non-inferior to concurrent if the upper limit of the 95% CI for the between-treatment (bimatoprost/timolol fixed combination minus concurrent) difference was ≤ 1.5 mmHg. Adverse events were collected and slit-lamp examinations were performed to assess safety. Between-group comparisons of the incidence of adverse events were performed using the Pearson chi-square test or Fisher's exact test.

RESULTSOf the enrolled 235 patients, 121 patients were randomized to receive bimatoprost/timolol fixed combination and, 114 patients were randomized to receive concurrent treatment. At baseline the mean value of mean diurnal IOP was (25.20 ± 3.06) mmHg in the bimatoprost/timolol fixed combination group and (24.87 ± 3.88) mmHg in the concurrent group. The difference between the treatment groups was not statistically significant. The mean change from baseline in mean diurnal IOP (± standard deviation) in the bimatoprost/timolol fixed combination group was (-9.38 ± 4.66) mmHg and it was (-8.93 ± 4.25) mmHg in the concurrent group (P < 0.01). The difference between the two treatment groups (bimatoprost/timolol fixed combination minus concurrent) in the change from baseline of mean diurnal IOP was -0.556 mmHg (95% CI: -1.68, 0.57, P = 0.330). The upper limit of the 95% CI was less than 1.5 mmHg, the predefined margin of non-inferiority. Adverse events occurred in 26.4% (32/121) of the bimatoprost/timolol fixed combination patients and 30.7% (35/114) of the concurrent patients. The most frequent adverse event was conjunctival hyperemia, which was reported as treatment related in 16.5% (20/121) in the bimatoprost/timolol fixed combination group and 18.4% (21/114) in the concurrent group (P > 0.05).

CONCLUSIONSBimatoprost/Timolol Fixed Combination administered in Chinese patients with open-angle glaucoma or ocular hypertension was not inferior to concurrent dosing with the individual components. Safety profiles were similar between the treatment groups.

Adolescent ; Adult ; Aged ; Amides ; administration & dosage ; adverse effects ; therapeutic use ; Bimatoprost ; Cloprostenol ; administration & dosage ; adverse effects ; analogs & derivatives ; therapeutic use ; Female ; Glaucoma, Open-Angle ; drug therapy ; Humans ; Male ; Middle Aged ; Ocular Hypertension ; drug therapy ; Timolol ; administration & dosage ; adverse effects ; therapeutic use ; Young Adult